British pharmaceutical exports to the United States will be shielded from punitive tariffs imposed by Donald Trump under a newly finalised bilateral deal, a move the government heralds as a major victory for the UK’s £21 billion life sciences sector. The agreement, confirmed on Thursday, makes the UK the first country to secure a complete, three-year exemption for its drug exports, protecting around £5 billion of annual sales from potential duties of up to 100%.
Tariff shield and trade gains
The Department for Science, Innovation and Technology announced the final version of the UK-US “partnership” on drug pricing and access in a press release after 5pm on Thursday, April 2, 2026. The deal builds on the US-UK Economic Prosperity Deal announced last May and ensures preferential terms for medical technology exports as well, with no new tariffs for at least three years. Ministers described it as “a win for British patients, British businesses and the British economy”, arguing it will protect 50,000 pharmaceutical jobs and encourage further investment in UK research and production. The Association of the British Pharmaceutical Industry (ABPI) welcomed the move, saying it would support the industry and ensure patient access to innovative medicines.
Increased NHS spending to access new drugs
In parallel with the tariff exemption, the deal commits the UK to significantly increase spending on new medicines, a move presented as accelerating patient access to cutting-edge treatments. The government has pledged to double its expenditure on newly developed medicines from 0.3% of GDP to 0.6% by 2035. To facilitate this, the National Institute for Health and Care Excellence (Nice) has already increased its cost-effectiveness threshold, raising the amount the NHS can spend on a treatment from £30,000 to £35,000 per quality-adjusted life year (QALY) gained.
This change, effective from this week, represents a 25% rise at the lower end of the previous £20,000-£30,000 range. The government highlighted the recent approval of two cancer drugs under this new regime as proof of its benefits: one for a gene-related brain cancer and a “last resort” treatment for a rare stomach cancer. The adjustment is intended to allow Nice to approve approximately three to five more drugs per year. Furthermore, the rebate rate for newer medicines under the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) will be capped at a maximum of 15% until the end of 2028, a measure aimed at providing stability for drug companies.
Mounting concern over the financial cost to the NHS
Critics, however, have voiced profound scepticism, arguing the deal’s financial mathematics pose a severe threat to NHS finances. Dr Andrew Hill, a drugs expert at the University of Liverpool, has estimated that the commitment to double medicines spending will cost the UK an additional £9bn a year by 2035. He starkly questioned the logic, stating: “Why spend an extra £9bn a year on higher drug prices to protect drug exports to the US of only £5bn a year? The maths simply does not add up.” Dr Hill added that the £9bn could save more lives if spent on expanding existing NHS services.
These concerns are echoed by health economists and opposition parties. Ed Wilson, a health economist, suggested that even if frontline services were protected, the increased drug bill would inevitably mean less money for other initiatives that might offer better value. The Liberal Democrats have labelled the agreement a “Trump shakedown of the NHS,” with the party’s health spokesperson, Helen Morgan, accusing the government of having “rolled over” to US demands. “Decisions over how to spend money in our NHS should be set by the British people, not by a foreign regime,” she said.
The campaign group Global Justice Now went further, describing the pact as an act of “corporate capture” that invites pharmaceutical companies onto a committee that will help shape NHS budgets. Its policy manager, Tim Bierley, criticised the government for making the agreement “without consulting parliament, confirmed it via press release with no full text, then snuck it out at the start of the Easter weekend.” The Liberal Democrats have demanded that MPs be allowed to scrutinise and vote on the deal, a call supported by Dame Chi Onwurah MP, Chair of the House of Commons Science, Innovation and Technology Committee, who called for greater transparency.
The full text of the deal was published on Thursday evening, after the initial announcement. The government, via Lord Patrick Vallance, the Minister for Science, Innovation, Research and Nuclear, has confirmed the increased medicines spending will be funded through the Department of Health and Social Care. Yet, with the NHS budget facing intense pressure, critics fear the £9bn annual cost will inevitably divert funds from other essential services. The deal also places Nice under new pressure to approve other drugs it previously rejected on value grounds, such as the breast cancer drug Enhertu, setting the stage for further difficult financial decisions.